Tyro Capital Management
NGNE icon

Tyro Capital Management’s Neurogene NGNE Stock Holding History

Tyro Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$8.47M Buy
+304,401
New +$10.9M 1.5% 20

Other funds holding NGNE

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.6B AUM 22.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Tyro Capital Management's NGNE Position: Q3 2026 in Review

Tyro Capital Management opened a new position in Neurogene (NGNE) in Q3 2026: 304,401 shares worth $8.47M. The stake represents 1.5% of the portfolio and ranks #20 among its holdings.

58 funds tracked by Wall St. Rank hold NGNE as of Q3 2026.

  • Tyro Capital Management held 304,401 shares of Neurogene worth $8.47M as of Q3 2026.
  • Neurogene was a new Tyro Capital Management position in Q3 2026.
  • Neurogene made up 1.5% of Tyro Capital Management's portfolio in Q3 2026, its #20 holding.
  • 58 funds tracked by Wall St. Rank held Neurogene as of Q3 2026.

Based on Tyro Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.